US 12,226,423 B2
Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
Shunlin Ren, Richmond, VA (US); Leyuan Xu, Richmond, VA (US); Yanxia Ning, Richmond, VA (US); Jin Koung Kim, Richmond, VA (US); WeiQi Lin, Emerald Hills, CA (US); Andrew R. Miksztal, Palo Alto, CA (US); Hongwei Wu, Cupertino, CA (US); and Min L. Lee, Saratoga, CA (US)
Assigned to Virginia Commonwealth University, Richmond, VA (US); Durect Corporation, Cupertino, CA (US); and The United States Government as Represented by The Department of Veterans Affairs, Washington, DC (US)
Filed by Virginia Commonwealth University, Richmond, VA (US); Durect Corporation, Cupertino, CA (US); and The United States Government as Represented by the Department of Veterans Affairs, Washington, DC (US)
Filed on Jun. 28, 2022, as Appl. No. 17/852,142.
Application 17/852,142 is a continuation of application No. 17/094,432, filed on Nov. 10, 2020, granted, now 11,406,646.
Application 17/094,432 is a continuation of application No. 16/320,079, abandoned, previously published as PCT/US2017/044840, filed on Aug. 1, 2017.
Claims priority of provisional application 62/370,024, filed on Aug. 2, 2016.
Claims priority of provisional application 62/470,578, filed on Mar. 13, 2017.
Prior Publication US 2023/0047788 A1, Feb. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/565 (2006.01); A61K 8/63 (2006.01); A61K 8/73 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 31/575 (2006.01); A61K 31/724 (2006.01); A61K 47/10 (2017.01); A61K 47/40 (2006.01); A61P 1/16 (2006.01); A61P 3/06 (2006.01); A61P 17/06 (2006.01); A61P 31/04 (2006.01); A61Q 19/00 (2006.01); C07J 31/00 (2006.01)
CPC A61K 31/565 (2013.01) [A61K 8/63 (2013.01); A61K 8/738 (2013.01); A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 31/575 (2013.01); A61K 31/724 (2013.01); A61K 47/10 (2013.01); A61K 47/40 (2013.01); A61P 1/16 (2018.01); A61P 3/06 (2018.01); A61P 17/06 (2018.01); A61P 31/04 (2018.01); A61Q 19/00 (2013.01); A61Q 19/004 (2013.01); A61Q 19/007 (2013.01); C07J 31/006 (2013.01)] 20 Claims
 
1. A pharmaceutical composition comprising:
5-cholesten-3,25-diol, 3-sulfate (25HC3S) or salt thereof, wherein the 25HC3S or salt thereof is present in the pharmaceutical composition at a concentration ranging from 0.1 mg/mL to 50 mg/mL; and
an aqueous vehicle comprising at least one buffer and at least one cyclic oligosaccharide comprising at least one of hydroxypropyl β-cyclodextrin and sulfobutyl ether β-cyclodextrin.